[1] 陈伟伟, 高润霖, 刘力生, 等. 中国心血管病报告2016[J]. 中国循环杂志,2017,32(6):521-530. [2] Holick MF.Vitamin D deficiency[J]. N Engl med,2007, 357(3):266-281. [3] Jono S, Ikari Y, Shioi A, et al.Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease[J]. Circulation,2002,106(11):1192-1194. [4] Kiechl S, Schett G, Wenning G, et al.Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease[J]. Circulation,2004,109(18):2175-2180. [5] Nybo M, Johnsen SP, Dethlefsen C, et al.Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy popu-lation[J]. Clin Chem,2008,54(12):1969-1974. [6] Lee JH, Gadi R, Spertus JA, et al.Prevalence of vitamin D deficiency in patients with acute myocardial infarction[J]. Am J Cardiol,2011,107(11):1636-1638. [7] Verdoia M, Schaffer A, Sartori C, et al.Vitamin D deficiency is independently associated with the extent of coronary artery disease[J]. Eur J Clin Invest,2014,44(7):634-642. [8] Daubail B, Jacquin A, Guilland JC, et al.Serum 25-hydroxyvitamin D predicts severity and prognosis in stroke patients[J]. Eur J Neurol,2013,20(1):57-61. [9] Li YC, Kong J, Wei M, et al.1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system[J]. J Clin Invest,2002,110(2):229-238. [10] Werner C, Pöss J, Böhm M.Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?[J]. Drugs,2010,70(10):1215-1230. [11] Tamez H, Kalim S, Thadhani RI.Does vitamin D modulate blood pressure?[J]. Curr Opin Nephrol Hypertens,2013,22(2):204-209. [12] Weng S, Sprague JE, Oh J, et al.Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice[J]. PLoS One,2013,8(1):e54625. [13] Chen S, Law CS, Grigsby CL, et al.A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation[J]. J Steroid Biochem Mol Biol,2010,122(5):326-332. [14] Shea MK, Booth SL, Massaro JM, et al.Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study[J]. Am J Epidemiol, 2008,167(3):313-320. [15] Timms PM, Mannan N, Hitman GA, et al.Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory da-mage in chronic disorders?[J]. QJM,2002,95(12):787-796. [16] Grigoropoulou P, Eleftheriadou I, Zoupas C, et al.The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease[J]. Curr Med Chem,2011,18(31):4813-4819. [17] Tousoulis D, Siasos G, Maniatis K, et al.Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease[J]. Int J Cardiol,2013,167(5):1924-1928. [18] Knudsen ST, Foss CH, Poulsen PL, et al.Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications[J]. Eur Endocrinol,2003,149(1):39-42. [19] Bennett BJ, Scatena M, Kirk EA, et al.Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice[J]. Arterioscler Thromb Vasc Biol,2006,26(9):2117-2124. [20] 马燕, 庞小芬, 张之梁, 等. 老年男性原发性高血压患者体内维生素D与骨代谢指标的水平及相关性分析[J]. 诊断学理论与实践,2015,14(3):262-266. [21] 汪思阳, 沈展, 沈婷婷, 等. 补充维生素D对骨质疏松症和骨量减少患者骨密度和骨折风险的影响[J]. 内科理论与实践,2016,11(2):80-83. |